Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles

Yi-Seul Yoon1,†, Yejin Jang1, Thomas Hoenen2, Heegwon Shin1, Younghoon Lee3 & Meehyein Kim1,*
1Virus Research Group, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Korea, 2Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems 17493, Germany, 3Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea

A chemical library comprising 2,354 drug-like compounds was screened using a transcription and replication-competent virus-like particle (trVLP) system implementing the whole Ebola virus (EBOV) life cycle. Dose-dependent inhibition of Ebola trVLP replication was induced by 15 hit compounds, which primarily target different types of G protein-coupled receptors (GPCRs). Based on the chemical structure, the compounds were divided into three groups, diphenylmethane derivatives, promazine derivatives and chemicals with no conserved skeletons. The third group included sertindole, raloxifene, and ibutamoren showing prominent antiviral effects in cells. They downregulated the expression of viral proteins, including the VP40 matrix protein and the envelope glycoprotein. They also reduced the amount of EBOV-derived tetracistronic minigene RNA incorporated into progeny trVLPs in the culture supernatant. Particularly, ibutamoren, which is a known agonist of growth hormone secretagogue receptor (GHSR), showed the most promising antiviral activity with a 50% effective concentration of 0.2 µM, a 50% cytotoxic concentration of 42.4 µM, and a selectivity index of 222.8. Here, we suggest a strategy for development of anti-EBOV therapeutics by adopting GHSR agonists as hit compounds. [BMB Reports 2020; 53(3): 166-171]

INTRODUCTION

The genus Ebolavirus belonging to the family Filoviridae comprises five different species: Zaire, Sudan, Bundibugyo, Reston and Tai Forest (1). Zaire ebolavirus [ZEBOV or simply Ebola virus (EBOV)] is an enveloped virus with a single-stranded, negative sense RNA genome measuring approximately 19,000 nucleotides in length (2). It encodes structural proteins including nucleoprotein (NP), envelope glycoprotein (GP), and the matrix protein VP40, in addition to VP24 (nucleocapsid-associated protein), VP30 (an activator of viral transcription), VP35 (a type I interferon antagonist and a polymerase cofactor) and RNA dependent RNA polymerase (L), and non-structural proteins such as sGP (3-6). Efficient viral infection requires at least two cellular receptors, the endo/lysosomal cholesterol transporter protein Niemann-Pick C1 (NPC1) and T-cell immunoglobulin and mucin domain 1 (TIM-1) (7, 8). The viral ribonucleocapsid (NC) consisting of the helical NP-viral RNA (vRNA) complex associated with VP24, VP30, VP35 and L is released into the cytoplasm after macropinocytosis (9). The negative sense vRNA is transcribed into mRNA for synthesis of viral proteins and complementary RNA for further vRNA amplification. During the final stage of the virus life cycle, the progeny virions are assembled at the plasma membrane via a VP40-dependent mechanism (10).

Since 1976 when this virus was first identified, its infection has caused Ebola hemorrhagic fever (EHF) in humans with average fatality rates exceeding 50% (available online at https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease). The West African EBOV epidemic from 2014 to 2016 was the worst recorded EHF outbreak in history, resulting in 28,639 suspected and laboratory-confirmed cases and 11,316 deaths (available online at https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html). More recently, the Zaire Ebola outbreak in the Democratic Republic of Congo caused at least 139 deaths as of August 2018 (11). Despite the high fatality rate, specific antiviral therapies are unavailable. Given the sporadic circulation of EBOV in Africa as well as the increased possibility of its international spread, it is imperative...
to develop prophylactic or therapeutic antivirals against EBOV infection (12).

Several high-throughput screening (HTS) methods, including monocistronic minigenome technology and pseudotyped viral particle systems, have been developed to identify antiviral compounds against EBOV (13-16). These strategies facilitated safe and robust screening of antivirals in biosafety level 2 (BSL2) facilities without the need for the highest-level bio-containment laboratory, BSL4, in which research with live EBOV is restricted. However, these methods enable limited targeting of the viral RNA transcription/replication or entry steps by the antiviral compounds. By contrast, the transcription and replication-competent virus-like particle (trVLP) system can be used to identify antiviral compounds by targeting virtually every stage of the viral life cycle (17). Here, the tetracistronic minigenome carrying a reporter gene and three viral genes encoding structural proteins VP40, GP and VP24, flanked by 5′-leader and 5′-trailer regions, are cloned under the T7 promoter in the negative-sense orientation. Co-transfection of this tetracistronic construct with five additional plasmids expressing viral proteins for RNA synthesis, including NP, VP30, VP35 and L, together with T7 RNA polymerase initiates transcription and replication of the minigenome and leads to generation of infectious progeny VLPs encapsulating the minigenome RNA. Eventually, trVLPs acquire the ability to infect other target cells expressing TIM-1 and the four viral proteins, NP, VP30, VP35 and L, for the second-round trVLP production. The aim of this study was to identify anti-EBOV compounds in a chemical library and to evaluate their antiviral efficacy using the trVLP system. Elucidation of the chemical structures of the resulting active compounds and the specific cellular targets provides scientific insight into the design of anti-EBOV drugs as well as their specific modes of action.

RESULTS

Screening of a chemical library

For high-throughput screening, we transfected and infected cells with the trVLP system derived from EBOV. After treatment of 2,354 small organic compounds, we measured their effects on the expression of both firefly luciferase (Fluc) and Renilla luciferase (RLuc), in which Fluc represents cell viability and RLuc denotes trVLP replication (Fig. 1). Based on the measurement of Fluc with 0.02% DMSO as a delivery vehicle, the average Z′ value was 0.61, with a signal-to-basal (S/B) ratio of 336 and a coefficient of variation (CV) of 13% (Fig. 1B). From the RLuc analysis with 0.02% DMSO, the average Z′ value was 0.57, with an S/B ratio of 450 and a CV of 14%. Z′ values in all plates were higher than 0.5, which suggested the reliability of the screening assay. We primarily selected 86 hits with relative RLuc values < 15% and Fluc values ranging between 80% and 120% at 10 μM (Fig. 1A, C).

Evaluation of antiviral and cytotoxic effects

Five-point dose-response curves with these 86 hits were analyzed with 3-fold dilutions from the initial concentration of 30 μM. Both 50% effective concentration (EC50) and 50% cytotoxic concentration (CC50) were calculated according to the simple two-point method using the RLuc and Fluc data, respectively (18). Fifteen compounds showed antiviral activity with selectivity indices (SI) exceeding 10 (Table 1). The majority of these compounds have been used to treat psychotic disorders or allergic diseases by binding to G protein-coupled receptors (GPCRs). This finding was partially consistent with previous reports of GPCR modulators as anti-EBOV compounds (19-21). Particularly, sertindole (EC50, 0.7 μM; SI, > 45.8), raloxifene hydrochloride (raloxifene; EC50, 0.3 μM; SI, 47.1) and ibutamoren mesylate (ibutamoren; EC50, < 0.4 μM; SI, > 81.1) showed the most prominent antiviral activity among the 15 major hit compounds. They were comparable or superior to the known anti-EBOV compounds such as ribavirin (RBV) and T-705 in their inhibitory effects.

To establish this finding, we purchased highly purified sertindole (≥ 97.5%), raloxifene (≥ 98%), and ibutamoren (≥ 98%) and repeated the antiviral assay using a wide range of concentrations of compounds (0.015 to 100 μM) (Fig. 2). Non-linear regression analysis revealed EC50 values of 1.5, 1.2, and 0.2 μM and the CC50 values of 23.1, 13.9, and 42.4 μM against HEK293T cells, respectively. However, the Fluc values...
Table 1. Anti-EBOV activity and cytotoxicity of the 15 hit compounds screened by dual luciferase assay using the trVLP system

| Hit no. | Compound                  | EC₅₀ (µM) | CC₅₀ (µM) | SI | Mode-of-action                                                                 |
|---------|---------------------------|-----------|-----------|----|-------------------------------------------------------------------------------|
| 1       | Homochlorcyclizine         | 0.8 ± 0.0 | > 30.0    | > 37.1 | Histamine H1-receptor antagonist                                                   |
| 2       | Loperamide                | 2.0 ± 1.3 | > 30.0    | > 18.6 | Opioid receptor agonist, Ca channel blocker                                      |
| 3       | Maprotiline               | 1.2 ± 0.7 | 25.1 ± 2.1| 26.9 ± 18.1 | Histamine H2 receptor inhibitor                                                   |
| 4       | Benztropine mesylate      | 3.1 ± 1.4 | > 30.0    | > 10.9 | Muscarinic acetylcholine M1 receptor antagonist                                  |
| 5       | Sertindole                | 0.7 ± 0.4 | > 30.0    | > 45.8 | Dopamine D2 receptor inhibitor, serotonin 5-HT receptor inverse agonist          |
| 6       | 3-CPMT¹                   | 1.3 ± 0.5 | > 30.0    | > 26.3 | Dopamine transporter inhibitor                                                   |
| 7       | Chlorcyclizine            | 2.7 ± 2.2 | > 30.0    | > 17.0 | Histamine H1 receptor antagonist                                                 |
| 8       | Clemastine fumarate       | 3.0 ± 0.5 | > 30.0    | > 10.2 | Histamine H1 receptor antagonist                                                 |
| 9       | Triflupromazine           | 1.4 ± 0.5 | > 30.0    | > 23.8 | Dopamine D1, D2 receptor antagonist                                              |
| 10      | Raloxifene                | 0.5 ± 0.0 | 25.6 ± 0.2| 47.1 ± 2.2 | Selective estrogen receptor modulator                                             |
| 11      | Perphenazine              | 2.7 ± 0.7 | > 30.0    | > 11.6 | Cytochrome P450 inhibitor, Ca antagonist                                         |
| 12      | Ibutamoren mesylate       | < 0.4     | > 30.0    | > 81.1 | Growth hormone secretagogue agonist                                              |
| 13      | Pipercetazine             | 2.0 ± 0.6 | 26.1 ± 5.5| 15.7 ± 4.6 | Dopamine receptor antagonist                                                    |
| 14      | SU11274                   | 2.6 ± 1.4 | > 30.0    | > 13.6 | c-Met inhibitor                                                               |

¹Half-maximal effective concentration estimated by the two-point method; ²half-maximal cytotoxic concentration by the two-point method; ³selectivity index, the ratio of CC₅₀ to EC₅₀; ⁴3a-(4-chlorophenyl)phenylmethoxy)troppane.

could have been affected by the transfection efficiency of the reporter plasmid rather than by cell viability. Thus, we performed another cytotoxicity assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Treatment of the mock cells with increasing concentrations of the compounds resulted in CC₅₀ values of 13.7 µM for sertindole, 23.4 µM for raloxifene, and 76.7 µM for ibutamoren (supplementary Fig. 1), comparable to those derived from the dual luciferase assay. These results indicated that subtoxic levels of the three compounds exhibit anti-EBOV activity.

Inhibition of viral protein expression and generation of viral progeny

To investigate whether the antiviral compounds reduce viral protein levels and generation of progeny trVLP, we performed immunoassays and quantitative RT-PCR (Fig. 3). Western blot assay showed that tetracistronic minigenome-derived VP40 was downregulated in a dose-dependent manner by sertindole, raloxifene and ibutamoren as well as RBV, a positive control, whereas the amount of another viral protein, NP, expressed via the plasmid-derived CAG promoter remained consistent (Fig. 3A). Confocal laser scanning microscopy also confirmed the reduction of cytoplasmic GP levels in the trVLP-infected cells (Fig. 3B). Total fluorescent spots per well were quantified by collecting images from 36 areas without any overlap in each sample triplicate. This wide-field imaging analysis revealed that the number of GP-positive spots was reduced significantly in the presence of 10 µM sertindole (by 84.7%), raloxifene (by 69.1%), or ibutamoren (by 74.2%) as well as 100 µM RBV (by 62.5%) (Supplementary Fig. 2). We investigated whether their inhibition suppressed the production of infectious trVLPs. Culture supernatants were harvested to quantify the relative amounts of the encapsidated tetracistronic minigenome RNA. After RT and touchdown PCR, quantitative PCR analysis was performed using EBOV-specific primer sets as described previously (22). The results revealed suppression of the amount of negative-sense minigenome RNA incorporated into trVLPs in a dose-dependent manner (Fig. 3C). These data strongly suggested that sertindole, raloxifene and ibutamoren not only prevent trVLP-derived EBOV viral replication in cells but also subsequently block the generation of trVLP progeny.

DISCUSSION

Here, we identified 15 anti-EBOV compounds with selectivity indices higher than 10 by screening a chemical library of compounds tested for clinical trials. Based on their target analysis, we found that GPCRs were closely linked to the EBOV life cycle. Using the same trVLP system, N. Lee et al. found GPCR modulators as antiviral hits, suggesting experimental reliability (19). However, in contrast to the previous study, from a technical perspective, we adopted the dual luciferase assay to measure the antiviral activity and cytotoxicity simultaneously from the same sample, while the cytotoxicity was determined in an image-based manner via Hoechst staining. Second, we evaluated the antiviral activity of the
Antiviral compound screening against Ebola virus
Yi-Seul Yoon, et al.

Fig. 2. Antiviral activity of highly purified sertindole, raloxifene, and ibutamoren. HEK293T cells were applied to the trVLP system in the presence of increasing concentrations of sertindole (A), raloxifene (B) or ibutamoren (C) using RBV (D) as a control. Percentage cell viability (black circles) and percentage trVLP replication (red squares) were assessed in FLuc and RLuc assays, respectively. EC_{50} and CC_{50} values were calculated via non-linear regression analysis using the GraphPad Prism 6 software. The means ± standard deviations of the EC_{50}, CC_{50}, and SI values are shown on the corresponding panels. These data are derived from two independent experiments in triplicate.

Fig. 3. Inhibition of viral protein expression and progeny trVLP generation. (A) Western blot analysis to detect VP40. Cells were transfected and infected with trVLP with increasing concentrations of each compound. On day 2 p.i., immunoblot analysis was performed with antibodies specific for VP40 (upper), NP (middle), or β-actin (lower). -V, no transfection and no infection control. M, trVLP-infected, DMSO-treated mock control. (B) Confocal microscopy for detection of viral GP. HEK293T cells were transfected and infected with trVLP and then treated with DMSO (0.2% v/v), 100 μM RBV, or 10 μM of each hit compound (sertindole, raloxifene or ibutamoren). On day 1 p.i., cells were fixed and permeabilized to probe the viral GP with an anti-GP antibody and an Alexa488-conjugated secondary antibody (green). Nuclei were counterstained with DAPI (blue). Original magnification, × 400. (C) Quantitative RT-PCR for measurement of trVLP RNA levels in the culture supernatants. HEK293T cells transfected with the plasmids mentioned above and infected with trVLP were treated with increasing concentrations of T-705, sertindole, raloxifene, or ibutamoren. On day 2 p.i., the trVLP RNA was purified from the supernatants and subjected to real-time RT-PCR with EBOV GP-specific primer sets. The experiment was performed in triplicate. Statistical significance was estimated using the DMSO-treated sample as a control. n.d., not detected. **P < 0.01; ***P < 0.001.

Among the selected hits, ibutamoren exhibited the most potent inhibitory effect against EBOV, with an EC_{50} of 0.2 μM, a CC_{50} of 42.4 μM and a SI of 222.8 (Fig. 2C). The compound (also called MK-677) is an orally active agonist binding to a GPCR, the growth hormone secretagogue receptor (GHSR), that is a known ghrelin receptor. This receptor increases GH levels, fat-free mass, and energy expenditure; however, due to increased cortisol levels, it has yet to be approved by the US Food and Drug Administration (FDA) (28, 29). Nevertheless, the anti-EBOV activity mediated via GHSR inhibition has implications for target discovery, because GHSR acts as a hub in the GPCR network of intra- or inter-family connections (30). The mechanism underlying its antiviral activity as well as evaluation of its efficacy against wild-type, highly pathogenic Ebola viral strains remains to be investigated. In the absence of any clinically available antiviral drug, this study informs that stimulation of GHSR represents a strategic and efficient approach for the development of a host-targeted anti-EBOV drug.
MATERIALS AND METHODS

Cells, plasmids and chemicals
HEK293T cells were purchased from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; HyClone) supplemented with 10% fetal bovine serum (FBS; HyClone).

Plasmids used in this study were designed for the tetracistronic minigenome (p4cis-vRNA-RLuc) under the T7 promoter and for the expression of T7 RNA polymerase (pCAGGS-T7), viral proteins (pCAGGS-NP, -VP30, -VP35 and -L) and TIM-1 (pCAGGS-Tim1) under the chicken beta-actin (CAG) promoter. Their constructs were reported previously (17).

We obtained 2,354 chemicals either approved by or investigated in clinical trials undertaken by the FDA, the European Medicines Agency (EMA), or other agencies: 1,600 from the Pharmaka-1600 collection (MicroSource Discovery Systems), 326 from the Prestwick Chemical Library (Prestwick Chemical), 103 from the Tocriscreen Library (Tocris Bioscience), and 325 from an in-house library (the Korea Chemical Bank) deposited by domestic chemists. Highly purified sertrindole (≥ 97.5%) and ibutamoren (≥ 98%) were purchased from Sigma-Aldrich, and raloxifene (≥ 98%) from Santa Cruz Biotechnology. Control antiviral compounds, RBV and favipiravir (T-705; 6-flouro-3-hydroxy-2-pyrazinecarboxamide) were purchased from Sigma-Aldrich or chemically synthesized in-house (patent application no., EP1417967A4).

trVLP generation and cell-based HTS
HEK293T cells (2 × 10^4 cells per dish) were cultured in a 150-mm dish overnight and transfected with p4cis-vRNA-RLuc (4 μg), pCAGGS-T7 (4 μg), -NP (2 μg), -VP35 (2 μg), -VP30 (1 μg), and L (15 μg) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. On day 3 post-transfection, the culture supernatants from the samples prepared according to a previous report (22). Their aliquots were stored at −70°C before use.

HTS was performed in 96-well plates using the transfection/infection method. Briefly, HEK293T cells (3 × 10^4 per well) were cultured overnight and transfected with a plasmid set consisting of pCAGGS-NP (8 ng), -VP35 (8 ng), -VP30 (5 ng), -L (60 ng) together with pCAGGS-Tim1 (15 ng) as well as pEGFPLuc (0.1 ng; BD Bioscience Clontech), which contains Firefly luciferase (FLuc). The next day, cells were infected with trVLPs (P0) diluted 1:10 with culture medium in the presence of each test compound (10 μM) or RBV (100 μM). Following fixation and permeabilization, the cells were immuno-stained with an anti-GP antibody (Cat. no. 40304-T44; Sino Biological) and an Alexa 488-conjugated goat anti-rabbit antibody (Invitrogen), and counterstained with Vectashield mounting medium containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories). Confocal fluorescent images were acquired using Zeiss LSM 700 (Carl Zeiss). The number of GP-positive cells was quantified by collecting data from 36 nonoverlapping images per well in triplicate for each sample to analyze wide-field fluorescence occupancy (IncuCyte FLR; Essen BioScience).

Real-time reverse transcription-polymerase chain reaction (RT-PCR)
The level of tetracistronic minigenome RNA incorporated within trVLP (P1) was measured by harvesting the culture supernatants from the samples prepared according to a previous report (22). In brief, tetracistronic trVLP RNA was purified using a QIAamp Viral RNA kit (Qiaegen) on day 2 p.i. Following reverse-transcription, cDNA was applied to a touchdown PCR with an EBOV-specific primer set followed by quantitative PCR with another inner primer set using SsoFast EvaGreen Supermix (Bio-Rad) and the CFX96 real-time PCR detection system (Bio-Rad). To calculate the relative fold changes, the RNA level in the DMSO-treated, trVLP-infected culture supernatant was set at 1.

ACKNOWLEDGEMENTS
M. K. was supported by grants from KRICT (KK1803-E00 and KK2032-20). Y. L. was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea govern-
REFERENCES
The authors have no conflicting interests.

CONFLICTS OF INTEREST
The authors have no conflicting interests.

REFERENCES
1. Kuhn JH, Becker S, Ebihara H et al (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155, 2083-2103
2. Jun SR, Leuze MR, Nookaew I et al (2015) Ebola virus comparative genomics. FEMS Microbiol Rev 39, 764-778
3. Schumann M, Ganikte T and Muhlberger E (2009) Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 83, 8993-8997
4. McCarthy SE, Johnson RF, Zhang YA, Sunyer JO and Ebihara H (2015) Ebola virus VP40 interacts with NP to facilitate nucleocapsid assembly and genome packaging. Sci Rep 7, 11452-11460
5. Biedenkopf N, Schlereth J, Grunweller A, Becker S and Hartmann RK (2016) RNA Binding of Ebola Virus VP30 Is Essential for Activating Viral Transcription. J Virol 90, 7481-7496
6. Banardyga L, Hoenen T, Ambroggio X, Dunham E, Groseth A and Ebihara H (2017) Ebola virus VP40 interacts with NP to facilitate nucleocapsid assembly and genome packaging. Sci Rep 7, 7698
7. Carette JE, Raaben M, Wong AC et al (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343
8. Kondratowicz AS, Lemenneg NF, Sinn PL et al (2011) T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for zaire ebolavirus and lake victoria marburg-virus. Proc Natl Acad Sci U S A 108, 8426-8431
9. Sugita Y, Matsunami H, Kawaoka Y, Noda T and Wolf M (2018) Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex at 3.6 A resolution. Nature 563, 137-140
10. Jasenosky LD, Neumann G, Lukashchov I and Kawaoka Y (2018) Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex. Sci Rep 7, 11452-11460
11. Arie S (2018) Ebola: WHO expresses "very serious concern" about Congo outbreak. BMJ 367, k7430
12. Cohen NJ, Brown CM, Alvarado-Ramy F et al (2016) Travel and border health measures to prevent the international spread of Ebola. MMWR Suppl 65, 57-67
13. Edwards MR, Pietzsch C, Vautselin T, Shaw ML, Bukreyev A and Basler CF (2015) High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication. ACS Infect Dis 1, 380-387
14. Kouznetsova J, Sun W, Martinez-Romero C et al (2014) Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3, e84
15. Wang Y, Cui R, Li G et al (2016) Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res 125, 1-7
16. Welch SR, Guerrero LW, Chakrabarti AK et al (2016) Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Res 136, 9-18
17. Hoenen T, Watt A, Mora A and Feldmann H (2014) Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetra-cistrionic minigenomes. J Virol Exp, 52381
18. Nevozhay D (2014) Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays. PLoS One 9, e106186
19. Lee N, Shum D, Konig A et al (2016) High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system. Antiviral Res 158, 226-237
20. Fan H, Du X, Zhang J et al (2017) Selective inhibition of Ebola virus entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Sci Rep 7, 41226
21. Cheng H, Lean-Rosney CM, Johansen L et al (2015) Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. J Virol 89, 9932-9938
22. Watt A, Moukambi F, Banardyga L et al (2014) A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J Virol 88, 10511-10524
23. Thome N, Shen M, Lea WA et al (2012) Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. Chem Biol 19, 1060-1072
24. Atwood BK, Lopez J, Wager-Miller J, Mackie K and Straiker A (2011) Expression of G protein-coupled receptors and related proteins in HEK293, AT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12, 14
25. Jung E, Nam S, Oh H et al (2019) Neutralization of acidic intracellular vesicles by niclosamide inhibits multiple steps of the dengue virus life cycle in vitro. Sci Rep 9, 8682
26. Kim J, Shin JS, Ahn S, Han SB and Jung YS (2018) 3-Aryl-1,2,4-oxadiazole derivatives active against human rhinovirus. ACS Med Chem Lett 9, 667-672
27. Jang Y, Shin JS, Yoon YS et al (2018) Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and viral matrix protein 2 function. J Virol 92, e01441-18
28. Svensson J, Lonn L, Jansson JO et al (1998) Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 83, 362-369
29. Patchett AA, Nargund RP, Tata JR et al (1995) Design and biological activities of L-163,191 (MK-0677): a potent, oral selective growth hormone secretagogue. Int J Mol Sci 785708590